

Fig. 1-A



Fig. 1-B


17000
16000
15000
14000
13000
12000
11000
10000
9000
8000
7000
6000
5000
4000
3000
2000
1000
0
Lin (Counts)
2
10
20
30
2-Theta - Scale

Fig. 1-C


Size: 0.6360 mg
Method: 10 DEG C/MIN AMB TO 300
Comment: SEALED PAN
237.55°C
78.14 J/g
240.25°C
Heat Flow (W/g)
1
0
-1
-2
-3
0
50
100
150
200
250
300
Exo Up
Temperature (°C)
Universal V2 5I

Fig. 2-A


Size: 1.7840 mg
Method: 10 DEG C/MIN AMB TO 300
Comment: SEALED PAN
237.27°C
72.23(76.83) J/g
4.601 J/g
247.95°C
241.51°C
Heat Flow (W/g)
1.5
1.0
0.5
0.0
-0.5
-1.0
-1.5
0
50
100
150
200
250
300
Exo Up
Temperature (°C)
Universal V2 5I

Fig. 2-B


Size: 1.4230 mg
Method: 10 DEG C/MIN AMB TO 300
Comment: SEALED PAN
2.0
1.5
1.0
0.5
0.0
Heat Flow (W/g)
225.40°C
61.13 J/g
236.56°C
0
50
100
150
200
250
300
Exo Up
Temperature (°C)
Universal V2 5I

Fig. 2-C


Size: 1.0400 mg
Method: 10 DEG C/MIN AMB TO 300
Comment: SEALED PAN
247.96°C
77.37 J/g
250.67°C
Heat Flow (W/g)
1
0
-1
-2
-3
-4
0
50
100
150
200
250
300
Exo Up
Temperature (°C)
Universal V2 5I

Fig. 2-D


Sample Weight: 15.300 mg
Comment:
N-Propyl Alcohol solvate 1
unsealed pan
Peak = 97.656 °C
Area = 812.715 mJ
Delta H = 53.055 J/g
Y1 = 10.9944 mW
X1 = 76.136 °C
Y2 = 10.3728 mW
X2 = 107.914 °C
Peak = 150.935 °C
Area = 632.462 mJ
Delta H = 41.337 J/g
Peak = 238.439 °C
Area = 660.30 mJ
Delta H = 43.157 J/g
X1 = 216.761 °C
Y1 = 18.2223 mW
X2 = 244.156 °C
Y2 = 20.1698 mW
Peak = 07.952 °C
Area = 282.646 mJ
Delta H = 18.474 J/g
X1 = 46.185 °C
Y1 = 7.6301 mW
X2 = 75.771 °C
Y2 = 10.9437 mW
X1 = 126.642 °C
Y1 = 2.1427 mW
X2 = 162.703 °C
Y2 = 13.9606 mW
Heat Flow Endo Up (mW)
Temperature (°C)
40
30
20
10
0
-10
-20
-30
-35.3
25
40
60
80
100
120
140
160
180
200
220
240
250

Fig. 2-E


98
96
94
92
90
88
Transmittance
3500
2500
1800
1400
1000
600
Wavenumber (cm-1)

Fig. 3-A


Transmittance
96
94
92
90
88
3500
2500
1800
1400
1000
600
Wavenumber (cm-1)

Fig. 3-B


100
98
96
94
92
90
Transmittance
3500
2500
1800
1400
1000
600
Wavenumber (cm-1)

Fig. 3-C


110
90
70
50
Transmittance
3500
2500
1800
1400
1000
Wavenumber (cm-1)

Fig. 3-D



Fig. 4



Fig. 5


e: 3.3010 mg
:hod: 10 dog ramp to 300 deg
methyl ethyl ketone solvent
55.79°C(I)
1.578%
(0.05208mg)
55.69°C
59.31°C
38.04°C(I)
2.903%
(0.09583mg)
36.21°C
39.73°C
82.83°C(I)
8.006%
(0.2643mg)
79.34°C
88.71°C
100
90
80
70
60
0
50
100
150
200
250
300
Temperature (°C)
Universal V2 5I

Fig. 6-A



Fig. 7



Fig. 8



Fig. 9



Fig. 10


Form I Peaks
Normalized Intensity
(d)
(c)
(b)
(a)
5
10
15
20
25
30
Degrees Two Theta

Fig. 11


Normalized Intensity
Form I Peak
(b)
(a)
5
10
15
20
25
30
Degrees Two Theta

Fig. 12



Fig. 13


Normalized Intensity
Form I Peak
(d)
(c)
(b)
(a)
5
10
15
20
25
30
Degrees Two Theta

Fig. 14


Actual Purity
100.3
100.3
B-
100.5
100.3
Purity
C+
99.2
98.3
End Point
B-
C-
A-
99.5
98.1
A+
Cooling Rate

Fig. 15


Half Normal Plot
Purity
A: Cooling Rate
B: Purity
C: End Point
Half Normal % Probability
99
97
95
90
85
80
70
60
40
20
0
B
A
AB
0.00
0.38
0.76
1.14
1.53
Effect

Fig. 16


Interaction Graph
Actual Purity
100.50
100.10
99.70
99.30
98.90
98.50
98.10
Actual Purity
B+
B-
B+
B-
A-
A+
Interaction of A: Cooling Rate and B: Purity

Fig. 17


Actual Form
0
0
B-
0
0
Purity
31
29
C+
End Point
B-
0
9
C-
A-
A+
Cooling Rate

Fig. 18


Half Normal Plot
Form
A: Cooling Rate
B: Purity
C: End Point
Half Normal % Probability
99
97
95
90
85
80
70
60
40
20
0
B
BC
C
0.00
4.31
8.62
12.94
17.25
Effect

Fig. 19



Interaction of B: Purity and C: End Point

Fig. 20



Fig. 21


15.3
14
12
10
8
6
4
2
0.478
Heat Flow Endo Up (mW)
25
40
60
80
100
120
140
160
180
200
220
240
259.1
Temperature (°C)
Peak = 241.462 °C
Onset = 239.599 °C
Area = 64.525 mJ
Delta H = 33.295 J/g
X1 = 232.698 °C
Y1 = 7.1811 mW
X2 = 243.648 °C
Y2 = 7.7216 mW
Y1 = 5.3624 mW
X1 = 88.630 °C
Y2 = 4.8904 mW
X2 = 108.088 °C
Area = -55.217 mJ
Delta H = -28.492 J/g
Onset = 103.241 °C
Peak = 105.185 °C
Peak = 246.827 °C
Onset = 245.009 °C
Area = 77.936 mJ
Delta H = 40.215 J/g
X1 = 243.648 °C
Y1 = 7.7216 mW
X2 = 251.200 °C
Y2 = 6.1701 mW

Fig. 22

Systolic Blood Pressure in Angiotensin II- or Vehicle-Infused Rats



Fig. 23

Eplerenone Prevents the Vascular Inflammatory Lesions in Angiotensin II/Salt Hypertensive Rats



Vehicle

Eplerenone

Fig. 24

COX-2 is Not Expressed in the Heart of 1% NaCl-Drinking Rats



1% NaCl

FIGURE 25

Angiotensin II/NaCl Treatment Induces COX-2 Expression in the Media of Coronary Arteries in Rats

Angiotensin II + NaCl

FIGURE 26

Eplerenone Prevents COX-2 Expression in Coronary Arteries in Angiotensin II/Salt Hypertensive Rats



Angiotensin II + NaCl + Eplerenone

FIGURE 27

Osteopontin is Not Expressed in the Normal Heart



Saline-Drinking Control

FIGURE 28

Eplerenone Prevents Osteopontin Expression in Coronary Arteries of Aldosterone/Salt/Uninephrectomized Rats



Aldosterone/Salt



Aldosterone/Salt with Eplerenone

FIGURE 29

Eplerenone Prevents Myocardial Osteopontin Upregulation in Aldosterone/Salt Hypertensive Rats



FIGURE 30

Eplerenone Prevents Myocardial COX-2 Upregulation in Aldosterone/Salt Hypertensive Rats



*** P<.001 vs NaCl
†† P<.01 vs Aldo/NaCl

FIGURE 31

Eplerenone Prevents Myocardial Injury in Aldosterone/Salt/Uninephrectomized Rats



FIGURE 32

COX-2 and Osteopontin are Co-Expressed in Similar Regions in the Coronary Arterial Wall



COX-2

Osteopontin

FIGURE 33

Potential Mechanisms of Aldosterone-Induced Vascular Inflammation and Injury



43/55

FIGURE 34

Urinary Protein Excretion in Saline-Drinking Stroke-Prone SHR



*** P<.001vs Captopril
P<.001 vs Captopril+Ang II+Epl

FIGURE 35

Histopathologic Scores for Renal Injury in Saline-Drinking Stroke-Prone SHR

	Vehicle (n=8)	Capt (n=10)	Capt ALDO (n=7)	Capt Ang II (n=7)	Capt+Ang II+ Eplerenone (n=7)
Renal arteriopathy (lesions/100 glom.)	18±3**	0±0	15±1**	16±2**	3.6±1**, ##
Glomerular damage (lesions/100 glom.)	24±3**	0±0	26±1**	15±3**	3.2±1**, ##

** P<.001 vs Captopril
P<.001 vs Captopril & Ang II

FIGURE 36

Eplerenone Prolongs Survival and Protects Against Stroke in Saline-Drinking Stroke-Prone SHR







FIGURE 37

Eplerenone Protects Against Cerebral Injury in Saline-Drinking Stroke-Prone SHR



Vehicle-Treated
SHRSP



Eplerenone-Treated
SHRSP

FIGURE 38

Time-Course Expression of Myocardial COX-2 in Aldosterone-Salt Hypertensive Rats



FIGURE 39

Time-Course Expression of Myocardial Osteopontin in Aldosterone-Salt Hypertensive Rats



FIGURE 40

Time-Course Expression of Myocardial MCP-1 in Aldosterone-Salt Hypertensive Rats



FIGURE 41

Time-Course Expression of Myocardial ICAM-1 and VCAM-1 in Aldosterone-Salt Hypertensive Rats



FIGURE 42

Eplerenone Reduces Systolic Blood Pressure



FIG. 43



+ p<0.05 vs. Aldo

* p<0.05 vs. Veh

FIG 44


28 Day Circulating Osteopontin Levels
osteopontin (ng/ml)
1200.0
1000.0
800.0
600.0
400.0
200.0
0.0
*
+
VEH/1%NaCl
ALDO/1%NaCl
ALDO/1%NaCl+epl
* p<0.05 vs VEH; + p<0.05 vs ALDO/1%NaCl

FIG. 45



* p<0.05 vs. Veh + p<0.05 vs. Aldo

FIG. 46